UK Markets closed

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.1500-0.0700 (-2.17%)
At close: 04:00PM EDT
3.2400 +0.09 (+2.86%)
After hours: 06:06PM EDT
Full screen
Loading interactive chart…
  • Business Wire

    Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial

    SEATTLE, September 15, 2022--Omeros Corporation (Nasdaq: OMER) today reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Analysis in the randomized patient population shows that the addition of narsoplimab to treatment of critically ill patients with COVID-19 reduces the mortality risk (hazard ratio [HR]=0.81, with probability [HR <1] equal to 0.77). Narsoplimab showed the largest reduction in mortality risk to date acros

  • Business Wire

    I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19

    SAN FRANCISCO & SEATTLE, September 15, 2022--Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, and Omeros Corporation (NASDAQ: OMER), developer of the investigational agent narsoplimab, announced that enrollment has been closed and data have been analyzed in the narsoplimab arm of the I-SPY COVID Trial. The analysis in the randomized patient population, including those who declined treatment after randomization, shows that the addition of narsoplimab to treatment of

  • Business Wire

    Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab

    SEATTLE, August 17, 2022--Omeros Corporation (Nasdaq: OMER) today announced that the United States Food and Drug Administration (FDA) provided an interim response to the company’s formal dispute resolution request submitted to the Agency in June, appealing the earlier decision by the FDA review division to issue a complete response letter for the biologics license application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-